Drug intelligence / Profile preview

ShK-Dap22

Development stage
Preclinical
Lead developer
University of California, Irvine
Modality
Peptides
Administration
Subcutaneous, Intravenous
01

Overview

ShK-Dap22 is a synthetic peptide analog of the ShK toxin, which was originally isolated from the sea anemone *Stichodactyla helianthus*. It is designed as a potent and highly selective blocker of the voltage-gated potassium channel Kv1.3 (KCNA3). The modification involves substituting the lysine residue at position 22 with diaminopropionic acid (Dap), a change that significantly enhances its selectivity for Kv1.3 over other closely related channels such as Kv1.1, Kv1.2, and Kv3.1. ShK-Dap22 is widely utilized as a pharmacological research tool to study the role of Kv1.3 channels in immune cell functions, particularly in effector memory T cells and natural killer (NK) cells. While primarily used in preclinical research, Kv1.3 blockers like ShK-Dap22 are investigated for their therapeutic potential in treating autoimmune diseases and modulating the tumor microenvironment in cancer.

Other names
diaminopropionic acid 22-ShKShK-Dap22 peptideShK-Dap-22 peptideShK-Dap 22 peptide
02

Targets

HK1 (Hexokinase type I (mitochondrial))Kir (Inward-rectifier potassium channels)KCNA2 (Voltage-gated potassium channel subfamily A member 2)KCNA3 (Potassium voltage-gated channel subfamily A member 3)KCNA1 (Voltage-gated potassium channel subfamily A member 1)

Beyond the preview

Go deeper on ShK-Dap22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ShK-Dap22.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call